Evidence map›Paper›PMID 35725854›Full record

ReviewMolecular biology reports2022

Research progress and clinical application prospects of miRNAs in oral cancer.

Long Xing, Zhenghu Feng, Hongbing Nie, Meitian Liu, Yali Liu, Xiaohua Zhang, Haijing Zhou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Long XingNorthwest Minzu University, Lanzhou, China.ORCID http://orcid.org/0000-0003-1749-736X
Zhenghu FengNorthwest Minzu University, Lanzhou, China.
Hongbing NieNorthwest Minzu University, Lanzhou, China.
Meitian LiuNorthwest Minzu University, Lanzhou, China.
Yali LiuNorthwest Minzu University, Lanzhou, China.
Xiaohua ZhangNorthwest Minzu University, Lanzhou, China.
Haijing ZhouNorthwest Minzu University, Lanzhou, China. xl13919282618@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral cancer is one of the most common malignant tumors worldwide, and it is also one of the most important and difficult clinical problems to be solved. Due to the regional differences in diet culture, some areas have taken the 'hardest hit' of oral cancer cases. However, the existing clinical treatment methods (surgery as the main treatment method, radiotherapy and chemotherapy as the auxiliary ones) do not have satisfactory treatment effects; therefore, new diagnosis and treatment methods need to be developed and utilized. Micro RNAs (miRNAs), as a class of substances that play an important regulatory role in the development of tumors, have an important value in the diagnosis and treatment of various tumors. At the same time, many miRNAs have obvious expression differences in oral cancer tissues compared to normal tissues. Therefore, they may have diagnostic and therapeutic effects on oral cancer. In this review, we evaluate the miRNAs that play a regulatory role in the development of oral cancer and those that are expected to be applied in the diagnosis and treatment of oral cancer. At the same time, we summarize the important challenges that need to be addressed, aiming to provide evidence and suggestions for the application of miRNAs in the diagnosis and treatment of oral cancer.

Indexed as

MicroRNAsMouth NeoplasmsHumansMicroRNAsChemotherapy resistanceDiagnosismicroRNAOral cancerPrognosisTarget gene

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.